Greenville Health System Cancer Institute

Greenville, South Carolina 29615-4816

0 studies enrolling now · 13 studies all time

What they study most

B-Cell Malignancies, Bladder Cancer, Breast Cancer, Cancer, Cholangiocarcinoma, Colorectal Neoplasm, Endometrial Cancer, Gastric Cancer, Graft-versus-host Disease (GVHD), HER2 Positive Breast Cancer, Head and Neck Cancer, Hepatic Veno-Occlusive Disease

Studies at this site

• A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant — Completed
• Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) — Completed
• Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors — Stopped early
• An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants — Stopped early
• A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) — Completed
• Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) — Stopped early
• An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant — APPROVED_FOR_MARKETING
• Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers — Completed
• DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) — Completed
• Use of Heart Rate Variability (HRV) Biofeedback for Cancer Survivors — Completed
• A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer — Completed
• Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study — Completed
• MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients — Stopped early